Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NKTR-118 + rifampin
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
NKTR-118 + rifampin is an experimental drug combination consisting of NKTR-118 (pegylated naloxol, a peripherally acting mu-opioid receptor antagonist) and rifampin (an antibiotic and potent cytochrome P450 inducer). NKTR-118 (naloxegol) was developed for the treatment of opioid-induced constipation (OIC) and is designed to block opioid receptors in the gut with minimal central nervous system penetration due to its PEGylation. Rifampin is included in this combination specifically to study its effects on the pharmacokinetics of NKTR-118, since rifampin is known to be a strong inducer of various drug-metabolizing enzymes and transporters. The combination itself is not used therapeutically but rather to characterize drug–drug interactions and metabolism in clinical pharmacology studies in healthy volunteers[1][5]. Nektar Therapeutics initially developed NKTR-118; AstraZeneca has developed and marketed naloxegol as Movantik.
- Other names
- naloxegolNKTR-118NKTR118NKTR 118rifampicin
02
Targets
RNAP (Bacterial dna-dependent RNA polymerase)MOR (Mu opioid receptor)PXR (Pregnane X receptor)UGT (UDP-glucuronosyltransferase family)rpoB (DNA-directed RNA polymerase subunit beta)
Beyond the preview
Go deeper on NKTR-118 + rifampin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NKTR-118 + rifampin.